尼达尼布治疗结缔组织相关性间质性肺炎临床疗效研究  

Clinical efficacy of Nintedanib in the treatment of connective tissue-associated interstitial pneumonia

作　　者：向玉 曾宪升[2] 姚香萍 张帆[1] XIANG Yu;ZENG Xian-sheng;YAO Xiang-ping;ZHNAG Fan(Medical College,Wuhan University of Science and Technology,Hubei Wuhan 441021,China;Department of Respiratory and Critical Care Medicine,Xiangyang Central Hospital,Hubei Xiangyang 441201,China)

机构地区：[1]武汉科技大学医学部医学院,湖北武汉441021 [2]襄阳市中心医院呼吸与危重症医学二科,湖北襄阳441021

出　　处：《内科急危重症杂志》2024年第5期404-406,459,共4页Journal of Critical Care In Internal Medicine

基　　金：湖北省卫生健康委员会项目(WJ2023F071)。

摘　　要：目的:评估尼达尼布联合常规治疗对结缔组织相关性间质性肺炎(CTD-ILD)的疗效。方法:收集102例CTD-ILD患者作为研究对象,根据临床治疗方案不同将其分为常规治疗组(50例)和尼达尼布联合治疗组(52例),疗程6个月。比较2组患者治疗前、治疗6个月后临床症状、肺功能、肺部高分辨CT评分及血清细胞因子水平的变化。结果:尼达尼布联合治疗组血清细胞因子、肺部高分辨CT评分较治疗前明显降低,肺功能明显改善(P均<0.05)。结论:尼达尼布联合常规糖皮质激素抗炎治疗可降低CTD-ILD患者血清细胞因子水平,减轻体内炎症反应,改善肺功能,有助于延缓CTD-ILD患者的肺纤维化进展。Objective:To evaluate the efficacy of Nintedanib combined with conventional treatment for connective tissue-associated interstitial pneumonia(CTD-ILD).Methods:A total of 102 patients with CTD-ILD were collected and divided into conventional treatment group(50 cases)and Nintedanib combined treatment group(52 cases)for 6 months according to different clinical treatment plans.The changes of clinical symptoms,lung functions,high resolution CT scores and serum cytokine levels were compared before and 6 months after treatment in 2 groups.Results:The serum cytokines and lung high resolution CT scores in Nintedanib combined treatment group were significantly lower than those before treatment,and the lung function was significantly improved(all P<0.05).Conclusion:Nintedanib combined with conventional glucocorticoid anti-inflammatory therapy can reduce serum cytokine levels in CTD-ILD patients,reduce inflammation in vivo,improve lung function,and help delay the progression of pulmonary fibrosis in CTD-ILD patients.

关 键 词：结缔组织相关性间质性肺炎 尼达尼布 细胞因子 

分 类 号：R563.12[医药卫生—呼吸系统]